Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
| ▸ | CCR2 | P41597 | 1/20 | 0.35 |
| ▸ | ACKR3 | P25106 | 11/20 | 0.35 |
| ▸ | DRD2 | P14416 | 3/20 | 0.34 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.34 |
| ▸ | HTR1A | P08908 | 2/20 | 0.33 |
| ▸ | DRD4 | P21917 | 2/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL451087 | 0.81 | HSP90AA1 (0.34) | P2RX7KCNH2 | |
| SCHEMBL448046 | 0.78 | HSP90AA1 (0.56) | — | |
| SCHEMBL446122 | 0.73 | HSP90AA1 (0.31) | — | |
| SCHEMBL447775 | 0.71 | ALDH1A1 (0.31) | — | |
| SCHEMBL447710 | 0.70 | HSP90AA1 (0.51) | — | |
| SCHEMBL448071 | 0.69 | — | — | |
| SCHEMBL450199 | 0.68 | — | — | |
| SCHEMBL445764 | 0.68 | — | — | |
| SCHEMBL464703 | 0.67 | — | — | |
| SCHEMBL448855 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680100-B2 | Sulfonylhydrazide compounds for treating proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2014-03-25 | — | — | US | disclosed |
| US-8680100-B2 | Sulfonylhydrazide compounds for treating proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2014-03-25 | — | — | US | disclosed |
| US-20120065206-A1 | COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP. (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120065206-A1 | COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP. (US) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065206-A1 | COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS | PKD1, PKD2, PCNA | P2RX7 4614/4885CCR2 3742/4885ACKR3 1797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.